南方医科大学学报 ›› 2025, Vol. 45 ›› Issue (10): 2250-2257.doi: 10.12122/j.issn.1673-4254.2025.10.21

• • 上一篇    

丹蛭降糖胶囊通过下调Notch1/NICD/MAML1信号通路改善糖尿病肾病大鼠肾脏血管内皮功能

朱思佳(), 马竞成, 郑玉娇, 吴传云, 赵建根, 李玲秀, 汪莉, 周雪梅()   

  1. 安徽中医药大学中医学院,安徽 合肥 230000
  • 收稿日期:2025-05-15 出版日期:2025-10-20 发布日期:2025-10-24
  • 通讯作者: 周雪梅 E-mail:602536964@qq.com;410761221@qq.com
  • 作者简介:朱思佳,在读硕士研究生,E-mail: 602536964@qq.com
  • 基金资助:
    新安医学教育部重点实验室开放课题(2022XAYX10);新时代育人质量工程项目(研究生教育)(2023szsfkc085);安徽省科协青年科技人才托举计划项目(RCTJ202429)

Danzhi Jiangtang Capsule improves renal vascular endothelial function in rats with diabetic nephropathy by downregulating the Notch1/NICD/MAML1 signaling pathway

Sijia ZHU(), Jingcheng MA, Yujiao ZHENG, Chuanyun WU, Jiangen ZHAO, Lingxiu LI, Li WANG, Xuemei ZHOU()   

  1. College of Traditional Chinese Medicine, Anhui University of Chinese Medicine, Hefei 230000, China
  • Received:2025-05-15 Online:2025-10-20 Published:2025-10-24
  • Contact: Xuemei ZHOU E-mail:602536964@qq.com;410761221@qq.com

摘要:

目的 探讨丹蛭降糖胶囊通过Notch信号通路对糖尿病肾病(DN)模型大鼠肾脏血管内皮损伤进行修复的反应机制。 方法 随机将大鼠分为正常组、模型组、丹蛭降糖胶囊低、中、高剂量组、抑制剂组(n=10)。除正常组外,其余各组大鼠采取左肾切除术后高糖高脂饲料联合链脲佐菌素(STZ)注射建立DN模型。丹蛭降糖胶囊低、中、高剂量组分别按0.315、0.63、1.26 g/(kg·d)给药,抑制剂组以γ-分泌酶抑制剂DAPT20 mg/(kg·d)溶解于50%的CMC-Na溶液中隔天给药,正常组和模型组使用同等浓度生理盐水每天灌胃,连续给药4周。给药结束后用ELISA试剂盒检测肌酐(CRE)、尿素氮(BUN)、尿微量白蛋白(m ALB)水平,用透射电镜观察肾组织病理学变化,免疫组化法测量血管内皮生长因子(VEGF)、内皮素-1(ET-1)表达水平,Western blotting法测量血管内皮标志物CD31、Notch信号通路中Notch1、NICD、MAML1的蛋白表达,并比较各组数据。 结果 与正常组大鼠比较,模型组大鼠CRE、BUN、m ALB水平升高(P<0.01),电镜下肾脏出现病理损伤,肾脏组织中VEGF、ET-1、CD31表达升高(P<0.01),Notch1、NICD、MAML1水平上调(P<0.01);与模型组大鼠比较,丹蛭降糖胶囊组和抑制剂组的CRE、BUN、m ALB水平降低(P<0.05),电镜下肾脏病理变化也有明显好转,肾脏组织中VEGF、ET-1、CD31表达减少(P<0.05),Notch1、NICD、MAML1水平下调(P<0.05),其中丹蛭降糖胶囊高剂量组效果最好。 结论 丹蛭降糖胶囊治疗DN的机制可能与抑制肾组织中NICD、MAML1介导的Notch信号通路有关,进而调控内皮细胞VEGF、ET-1水平来改善大鼠血管内皮过度增殖、功能障碍的损伤状态。

关键词: 丹蛭降糖胶囊, 糖尿病肾病, Notch信号通路, 血管内皮功能, 肾功能

Abstract:

Objective To investigate the therapeutic mechanism of Danzhi Jiangtang Capsule (DZJTC) for repairing renal vascular endothelial injury in rats with diabetic nephropathy (DN). Methods Fifty male SD rat models of DN, established by left nephrectomy, high-sugar and high-fat diet and streptozotocin injection, were randomized into DN model group, low-, medium-, and high-dose DZJTC treatment groups, and DAPT (a γ-secretase inhibitor) treatment group, with 10 rats with normal feeding as the control group. DZJTC was administered by daily gavage at 0.315, 0.63, or 1.26 g/kg, and DAPT (20 mg/kg, dissolved in 50% CMC-Na solution) was given by gavage every other day for 4 weeks; normal saline was given in the control and model groups. After treatment, the levels of creatinine (CRE), blood urea nitrogen (BUN), and microalbuminuria (mALB) were detected with ELISA, and renal pathologies were observed by transmission electron microscopy. Renal expressions of vascular endothelial growth factor (VEGF) and endothelin-1 (ET-1) were measured by immunohistochemistry, and the protein expressions of CD31 and Notch signaling pathway components were detected using Western blotting. Results The rat models of DN showed significantly increased CRE, BUN, and mALB levels, obvious renal pathologies under electron microscopy, increased renal VEGF, ET-1 and CD31 expressions, and upregulated Notch1, NICD, and MAML1 protein levels. Treatment with DZJTC at the 3 doses and DAPT significantly reduced CRE, BUN, and mALB levels, improved renal pathology, decreased VEGF, ET-1 and CD31 expressions, and lowered Notch1, NICD and MAML1 levels, and the effects were the most pronounced with high-dose DZJTC. Conclusion DZJTC ameliorates hyperproliferation and dysfunction of renal vascular endothelium in DN rats possibly by regulating renal VEGF and ET-1 levels via inhibiting NICD- and MAML1-mediated Notch signaling pathway.

Key words: Danzhi Jiangtang Capsule, diabetic nephropathy, Notch signaling pathway, vascular endothelium function, renal function